We compared late side effects and quality of life (QoL) in 430 survivors of childhood acute leukaemia based on whether they had undergone haematopoietic cell transplantation (n ¼ 142) or not (n ¼ 288). Mean age was 18.2 years and mean follow-up duration was 11.9 years. Multivariate logistic regression analyses were performed to compare the risk of each type of late effect in the two groups. Based on age, VSP-A or SF36 questionnaires were used to assess QoL. For each QoL dimension, multiple linear regression was done to construct models of association with the treatment group. Transplanted patients experienced more side effects, including height growth failure, gonadal dysfunction, hypothyroidism and cataract. Children and adolescents in the two treatment groups reported similar QoL levels for almost all dimensions except a better perception of school work by young transplanted children and more difficulties in relating to the medical staff for transplanted adolescents. In adults, two differences in physical domain of QoL were detected but the calculated effect sizes were less than 0.2 in each case, suggesting an uncertain clinical significance. In spite of a higher risk of physical adverse events in the transplanted group, very few clinically significant differences in QoL are detectable.
Introduction
Cure of childhood cancer may be accompanied by a number of late adverse events. [1] [2] [3] Childhood acute leukaemia (AL) is now a curable disease in approximately 80% of patients with ALL and 50% of patients with AML. [4] [5] [6] [7] [8] [9] A significant proportion of survivors have undergone haematopoietic stem cell transplantation (HSCT). HSCT causes various adverse late effects, including short stature, gonadal dysfunction, thyroid insufficiency, cataract and second malignancies, especially when TBI has been used. [10] [11] [12] Long-term side effects have also been described in patients treated without HSCT, but they seem to be less frequent and for a large part related to prophylactic central nervous system (CNS) irradiation and to cumulative anthracycline dose. [13] [14] [15] Several studies have recently evaluated quality of life (QoL) among survivors of childhood cancer. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] However, it is not known if prior HSCT affects QoL of childhood AL survivors more than conventional treatment. We initiated a late effect program (the 'LEA' program) in 2003 for children with AL treated in two French geographic areas (west PACA-Corse and Lorraine) to study the health status and QoL of long-term survivors. Using data collected from this cohort, we present a comparison of late side effects and QoL after treatment with or without HSCT.
Methods

Subjects
Patients treated after January 1980 in two French paediatric cancer centres were asked to have a complete medical evaluation and to fill in a QoL questionnaire if they met all the following inclusion criteria: (1) a diagnosis of ALL or AML, (2) being under 18 at the time of the diagnosis and more than 8 at the time of the evaluation, (3) completion of chemotherapy or HSCT at least 1 year before inclusion in the study, (4) complete remission at the time of inclusion. Patients with Down's syndrome and those with a previous malignant disease were excluded. Among the 629 patients who fulfilled all these selection criteria, 430 agreed to participate in the complete evaluation program and are the subjects of this report. A total of 142 (33%) of the 430 participating patients had received HSCT as part of their treatment ('HSCT group'), whereas 288 (67%) had not ('chemotherapy group'). Inclusion of patients and data collection ran through the years [2004] [2005] . Mean follow-up duration from diagnosis to inclusion in the LEA program was 11.975.6 years.
Evaluation of medical health status
A detailed review of each medical record was performed and every medical event occurring after the end of therapy was reported. The program also included a medical visit at the time of inclusion in the study, to complete the late effect evaluation with a clinical examination and laboratory exams when needed.
Height, weight and body mass index (BMI) measured at the time of the diagnosis and at the time of inclusion were compared to normality and converted to standard deviation scores (SDs) using tables of normal values for the French population. 27, 28 The cumulative change in SD score was calculated as the SDs at the time of inclusion visit minus the SDs at diagnosis. Height growth failure was defined by a cumulative SDs change equal or lower than À1 (minor for a value between À1.0 and À1.9 and major for a value equal or lower than À2). Overweight was defined as a BMI of 25 or more (minor 25.0-29.9, major if 30 or more) for adults and by a cumulative SDs change of þ 1 or more (minor for a value between 1.0 and 1.9 and major for a value equal or higher than 2) for children under 18.
Children were considered not assessable for gonadal function if they were under 15 years and had never had menarche (girls) or did not have any pubertal signs (boys). In this study, a gonadal side effect was defined by a hypergonadotrophic hypogonadism (low oestradiol level with high follicle-stimulating hormone (FSH) and luteinising hormone (LH) in women and low testosterone with high FSH and LH in men) or by the occurrence of precocious puberty, and hypothyroidism by a non-transient elevation of thyroid stimulating hormone (TSH). A cardiac side effect was defined by abnormally decreased echocardiographic shortening fraction or if specific treatment was needed. An ophthalmological evaluation for detection of cataract was performed in patients who received TBI or prolonged steroid therapy. All second tumours (including basal cell carcinoma) were taken into consideration for this analysis. A viral side effect was defined as either hepatitis B surface antigen (HbsAg)-positivity, HIV-positivity or hepatitis C virus-positivity with detectable viral load. All other observed late side effects were noted in the category 'other late effects'.
Evaluation of the QoL
The VSP-A questionnaires (Ve´cu et Sante´Perc¸ue de l'Adolescent et de l'enfant) or the SF36 were used according to the age of the patient at the time of inclusion. The VSP-A questionnaires are generic health-related QoL (HRQL) questionnaires specifically designed for children and adolescents. They are developed from interviews with French children and adolescents, are well validated and appropriate to use in this population. [29] [30] [31] Different versions can be used: VPS-Ae (38 items, eight dimensions) is to be answered by 8-to 10-year-old children, VSP-A (39 items, 11 dimensions) by 11-to 17-year-old adolescents, and VSP-Ap (48 items, 11 dimensions) by children's or adolescents' parents. In addition to dimension-specific scores, a global HRQL score was computed.
SF-36 is a generic QoL scale for adults, consisting of 36 items describing eight dimensions and two calculated composite scores (the physical composite score and the mental composite score). It is a reliable instrument in assessing self-perceived health status in adult survivors of childhood cancer. 32 Its French version is well validated.
33,34
Statistical methods Statistical analysis of data was performed using SPSS version 10.1. w 2 tests and Student's t-tests were used to compare demographic and clinical variables as well as HRQL scores between the HSCT group and the chemotherapy group.
Multivariate logistic regression analyses with each type of physical late effect as the dependent variable were conducted to compare patients of the HSCT group to those of the chemotherapy group. Odds ratio (OR) of having one type of late effect (along with 95% confidence intervals) was estimated adjusted for the following covariates: gender, leukaemia subtype (ALL versus AML), age at diagnosis, relapse of the disease (yes, for a relapse occurring any time during follow-up versus no) and follow-up duration from diagnosis to inclusion. Multiple linear regression was used to construct models of association of each HRQL score (dependent variable) with the treatment group (HSCT group versus chemotherapy group) as the explanatory variable. Potential confounding factors were the same as in the physical late effect analysis. Each model was given with its standardized b-coefficient, standard error (s.e.) and significance of the association set as Po0.05.
To help interpret the clinical significance of differences in mean scores, effect sizes were calculated using mean scores adjusted to potential confounding factors (mean adjusted score in HSCT group-mean adjusted score in chemotherapy group/unadjusted s.d. in chemotherapy group). An effect size of 0.2-0.49 was considered as 'small', 0.5-0.79 as 'medium', and 0.8 or higher as 'large'. 35 According to Norman, an effect size of 0.5 corresponds to a minimum perceptible difference and thus can be considered a clinically important difference. 36 
Results
Eligible patients, comparison between participants and non-participants
Of the 629 patients who fulfilled all the selection criteria, 430 (68%) participated in the complete evaluation program; the other 199 being either lost to follow-up or declining to participate in at least one part of the study. The percentage of participants was similar in each paediatric cancer centre. To determine the potential for introducing bias into the studied cohort, we compared demographic, leukaemia-related and treatment-related characteristics among participants and non-participants. We found that these two groups were similar with regard to age at diagnosis, type of leukaemia and history of CNS or testicular irradiation but that the studied cohort included a higher percentage of female subjects (48 versus 39%, P ¼ 0.03) and a higher percentage of transplanted patients (33 versus 23%, P ¼ 0.01) than the non-participant group. When only transplanted patients were considered, participants and non-participants were similar with regard to type of transplantation (allograft versus autograft), disease status at the time of the transplantation (first CR versus more advanced), conditioning regimen (TBI or not) and occurrence of post transplant GVHD.
Studied cohort
Patients in the two treatment groups were similar in age and follow-up duration at inclusion ( Table 1) . As expected, the proportion of AML and the percentage of patients who had suffered relapse were higher in the HSCT group than in the chemotherapy group. In the HSCT group, we noted a significantly higher proportion of boys and a trend towards the child's being older at diagnosis.
In the chemotherapy group, 77 out of 288 (27%) had also received prophylactic CNS irradiation (62 cranial and 15 craniospinal; 18 Gy in 64 children and 21-24 Gy in 13) and six out of the 136 boys had had testicular irradiation. The mean time duration from the last chemotherapy to the study evaluation was 9.2 years.
In the HSCT group, 104 (73%) had had a TBI as part of their conditioning regimen; most commonly 12 Gy in six fractions and 3 days with lung shielding at 8 Gy. A 4-Gy testicular radiation boost had been added to TBI in 19 boys. Ninety-two children had received allogeneic and 50 autologous transplant. Haematological status at the time of the first transplantation was CR1 in 82 cases, CR2 in 56 and more advanced in four. Sixteen children had received a CNS irradiation and 11 a testicular irradiation before transplantation. Six had received two HSCT, because they had relapsed after a first transplantation. Among 92 allograft recipients, 61 (66%) had experienced post transplant acute (n ¼ 54) and/or chronic GVHD (n ¼ 28, 21 of them after prior acute GVHD). Overall, the mean time duration from the last HSCT to the study evaluation was 10.1 years.
Late physical side effects After adjustment for potential confounding covariates, the risk of late events proved significantly higher in the HSCT group than in the chemotherapy group for many categories of adverse effect (Table 2) . Indeed, survivors in the HSCT group were more likely to have major height growth failure (OR, 10.5), gonadal dysfunction (OR, 24.7), hypothyroidism (OR, 54.6), cataract (unadjusted OR, 4.2) and to receive growth hormone (OR, 19.5). Patients in the HSCT group were also 2.2 times as likely as those in the chemotherapy group to suffer from at least one adverse event classified in the category 'other late effects'. In this category of 'other late effects', the most frequently detected were osteonecrosis, alopecia, neurological dysfunction, spinal deformity, renal failure, hearing loss, osteoporosis, diabetes and lipid abnormalities.
Quality of life
As shown in Tables 3 and 4 , scores reported by transplanted and non-transplanted children and adolescents were similar for all VSP-Ae subscales and all VSP-A subscales except for the 'school performance' and the 'relations with the medical staff' dimensions. Children in the HSCT group reported a significantly better perception of their school performances when compared to the chemotherapy group. Adolescents in the chemotherapy group reported better relations with medical staff than in the HSCT group, whereas the trend towards a higher score in the HSCT group for younger children was not statistically significant. Overall, the summary scores reported by the HSCT and chemotherapy groups were not significantly different. Similarly, comparing the data reported by the parents, we were unable to detect any differences between the transplanted and the non-transplanted group (Table 5) .
In adults (Table 6) , there were statistically significant differences in the subscale 'General health' and in the physical composite score, both differences showing a better score in the chemotherapy group when compared to the HSCT group. The calculated effect sizes were however less than 0.2 in both cases. We also detected a trend towards a higher score in the chemotherapy group for the subscale 'Role: physical' (evaluation of limitations due to physical status), although this trend was slightly below the threshold of statistical significance.
Discussion
Our findings indicate that very few clinically significant differences in QoL are detectable between HSCT and non-HSCT groups in spite of a higher incidence of physical adverse events in the HSCT group. Height growth failure, hypothyroidism and cataracts are well-known complications of HSCT, especially when the conditioning regimen includes TBI. 11, 37, 38 Moreover, hypogonadism is a major concern after BU-containing conditioning regimen as well as after TBI, 39 whereas, as suggested in this study, most children treated for leukaemia with chemotherapy alone will apparently have normal endocrine gonadal function. The risk of second malignancy has been associated with TBI in transplanted recipients and to CNS irradiation in children treated without HSCT. [40] [41] [42] Heart failure is known to be mainly linked to the cumulative anthracyclin dose, female gender and young age at treatment, but mediastinal irradiation in the context of TBI can worsen the anthracyclin effect. 43, 44 Overweight has been identified in leukaemia patients treated without HSCT, mainly in young girls who received prophylactic CNS irradiation. 45 The incidence and risk factors of this complication after HSCT is currently largely unknown. In our study, the trend towards a lower risk of overweight in the HSCT group has not been confirmed in the multivariate analyses. Our study has also detected differences in the QoL of adult survivors, in each case adversely affecting transplanted patients. These differences are limited to the physical composite score of SF36 and to one of its subscales ('General health'), whereas the mental dimensions are similar. Furthermore, effect sizes are less than 0.2 for both differences and consequently, their clinical importance remains uncertain. Additionally, we have reported a non-statistically significant trend towards a lower score in the transplanted group for the subscale 'Role: physical'. A small but statistically significant b Potential confounders included in the models are : gender, leukaemia subtype (ALL versus AML), age at diagnosis, relapse of the disease (yes, for a relapse occurring any time during follow-up versus no.) and follow-up duration from diagnosis to inclusion. impairment in the physical domain of SF36 (subscale 'Role: physical') has been noted in the leukaemia subgroup of a large Canadian cancer survivor cohort, when compared to Canadian normal population. 20 The contribution, if any, of transplanted patients in the difference was not mentioned. Interestingly enough, the scores observed in our chemotherapy group for the subscales 'General health' and 'Role: physical' (76.0721.6 and 88.7724.3) are similar to the scores reported for the Canadian control population (mean, 76.4 and 87.3) and similar to the normal value described in the French population. 33, 34 A recent report from the US Childhood Cancer Survivor Study has also demonstrated an increased risk for functional limitations in physical performance in all cancer types (including leukaemia) when compared to control siblings. 17 As in the Canadian study, the authors had not individualized a transplanted group. In the British Childhood Cancer Survivor Study, however, no evidence was found that survivors other than survivors of CNS and bone tumours scored significantly below UK-norms on the physical composite score of SF36. 26 Little information is available in survivors under 18. A Canadian study has compared parent-reported HRQL of child and adolescent cancer survivors to that of controls who had had no history of cancer. In the leukaemia subgroup, clinically important differences with controls have been found in the physical composite score with a slight difference in the psychosocial summary score. 19 At the opposite, using children self-report from the Minneapolis-Manchester QoL-youth form, another study has found that scores are as good or even better in cancer survivors than in age-matched controls. 18 We have used both parent-reported and child self-reported responses for children and adolescents under 18 and have found similar results in the transplanted and the non-transplanted groups for almost all dimensions except for the dimension 'school work' in the young children and the dimension 'relations with medical staff' in adolescents. The dimension 'school work' includes both the child's evaluation of his school results and how he feels satisfied with these results.
The dimension 'relations with medical staff' explores how the patient perceives the quality of relation with his doctors, nurses and psychologists. We acknowledge that the clinical significance of the differences observed in these dimensions is questionable. Transplanted children have reported a better perception of their school performances, but the score of non-transplanted children (70.4723.7) is similar to the normal value in the French population (70.4724.2). 31 Transplanted adolescents have reported more difficult relations with the medical staff than adolescents in the chemotherapy group, but the trend observed in younger children proved otherwise.
In the results presented here, there is a contrast between a clearly higher risk of medical adverse effects in our HSCT group and an apparently limited impairment in the QoL. This might indicate that patients have adapted relatively well in spite of their physical handicap, a hypothesis that has previously been proposed in other long-term cancer survivor studies. 20, 46 A similar finding has also been reported in the context of nonmalignant chronic diseases. Adaptation and acceptance of a handicap can allow patients facing their chronic condition to have a better QoL. 30, 47 Some limitations of our study must however be underlined. First, the absence of statistically significant differences between the transplanted and non-transplanted groups in most aspects of the QoL could indicate a lack of power of the study because of a too small number of patients. This limitation has been worsened by the fact that three different questionnaires had to be used due to a large range in the patients' age, resulting in a decreasing number of patients in each age group. Noteworthy, however, the absolute scores observed in both groups are quite similar in many subscales, suggesting that if a difference really existed, it would probably be small. In addition, when the 8-to 10-year-old and the 11-to 18-year-old groups were pooled by using parental version of VSP-A, responses to all domains of the questionnaire were remarkably similar in both groups. Another major concern arises from the fact that some differences adversely affecting QoL of transplanted patients have been detected in adults and not in younger survivors. This could suggest that impairment will appear even in the younger group during their adulthood. The consequences of some late effects, such as hypogonadism for instance, are obviously more likely to adversely affect the QoL in adulthood than in younger patients. We conclude that among leukaemia survivors, transplanted patients constitute a particularly high-risk population for late health status impairment. Early detection and prolonged monitoring of long-term side effects is an essential part of their overall health care. In spite of this high risk of physical adverse effect, clinical consequences on the QoL appear relatively mild.
